The UK and US have reached a significant bilateral deal that will guarantee no duties on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This move guarantees that duties on these key products will remain at nothing for a duration of the next three years.
This development follows earlier threats to hike import taxes on patented drug imports, with figures discussed up to one hundred percent.
"This arrangement between the UK strengthens the global environment for innovative medicines and brings much-needed balance to transatlantic drug exports," a statement said.
Trade Impact
Pharmaceuticals represent one of the UK's biggest export categories to the US, which is easily the primary market for large UK drugmakers.
Statistics reveal that in the year leading up to September, the UK shipped drugs worth billions to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This agreement protects work, stimulates funding and facilitates the UK to become a global hub for life sciences," a minister remarked.
Detailed NHS Changes
The pact includes several key changes from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. In the past, rebates topped twenty percent.
Recent Tensions
The pact follows a long-running row between the sector and the UK government over drug pricing and approval rates.
The disagreement were heightened by claims that US consumers were charged significantly more for the identical medicines than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial investments have been pledged toward projects in the United States.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had declined as a percentage of its resources over the last ten years.
